Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417693 | 1.00 | KDM4E (0.62) | KDM4ETSHRTP53ALDH1A1HTT | |
| SCHEMBL7956523 | 0.93 | ALDH1A1 (0.62) | KDM4ETSHRTP53ALDH1A1HTT | |
| SCHEMBL17296296 | 0.92 | ALDH1A1 (0.68) | KDM4ETSHRTP53ALDH1A1HTT | |
| SCHEMBL29417804 | 0.89 | LTA4H (0.61) | KDM4EALDH1A1HTTLTA4HSMN1; SMN2 | |
| SCHEMBL1283353 | 0.89 | LTA4H (0.61) | KDM4EALDH1A1HTTLTA4HSMN1; SMN2 | |
| SCHEMBL22084060 | 0.88 | KDM4E (0.57) | KDM4ETSHRTP53ALDH1A1HTT | |
| SCHEMBL29417616 | 0.87 | BACE1 (0.62) | KDM4ETSHRALDH1A1HTTLTA4H | |
| SCHEMBL4965868 | 0.87 | BACE1 (0.62) | KDM4ETSHRALDH1A1HTTLTA4H | |
| SCHEMBL14578276 | 0.85 | ALDH1A1 (0.69) | KDM4ETSHRTP53ALDH1A1HTT | |
| SCHEMBL9080753 | 0.85 | SMN1; SMN2 (0.50) | KDM4ETSHRTP53ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3787669-A1 | COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | The Trustees of Indiana University (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6297274-B1 | SUBSTITUTED 5-HYDROXYFURANONES | WARNER-LAMBERT COMPANY | 2001-10-02 | — | — | US | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0813534-A4 | 6-ARYL PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0813534-A1 | 6-ARYL PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997037985-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS WITH INCREASED WATER SOLUBILITY | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1996028448-A1 | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-4336374-A | HYPOGLYCEMIC AGENTS | NIPPON SHINYAKU CO., LTD. (JP) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | KDM4E 4221/4885TSHR 1206/4885TP53 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.